The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
September 29th 2024
Finerenone is at least as effective in patients who are in the hospital or were recently hospitalized for heart failure as those with stable condition, said Akshay Desai, MD, of Brigham & Women’s Hospital.
September 27th 2024
Risk Prediction for Risk Mitigation in Prostate Cancer Explored in New Study
January 14th 2023The importance of identifying rare pathogenic mutations and genetic risk score among patients was explored in this new analysis, with goals that included reducing mortality and early disease detection.
Read More
Investigators Find Potential Biomarker for Platinum-Based Chemotherapy Response in NSCLC
January 10th 2023Patients who had non–small cell lung cancer (NSCLC) with homologous recombination gene mutations had better outcomes, although no single gene in the pathway appeared to have a causal role.
Read More
Concurrent Antibiotics, Steroids Raise CDI Risk in People With Lung Cancer Receiving EGFR-TKIs
January 9th 2023The new report found no evidence that second-generation tyrosine kinase inhibitors (TKIs) were more likely to lead to Clostridioides difficile infection (CDI) in patients with lung cancer.
Read More
Interleukin-13, Periostin Show Potential as Biomarkers in Prurigo Nodularis
January 7th 2023Levels of certain biomarkers of inflammation in prurigo nodularis were evaluated between patients with and without the chronic inflammatory skin disorder, with the goal of showing potential for precision medicine in prurigo nodularis.
Read More
Impact of Patient Factors on Developing AML After MDS or CML; Ponatinib in Highly Resistant CP-CML
January 7th 2023Research presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition examined how certain patient and demographic characteristics that may be related to socioeconomic disparities impact the risk of hematological cancers; the influence of diabetes on chronic myeloid leukemia; and 2 updates on ponatinib.
Read More
Administering Antimicrobial Therapy Before CIT May Be Safer Option in NSCLC
January 5th 2023This study investigated the effects of antimicrobial therapy among patients with non–small cell lung cancer (NSCLC) who received immunotherapy with a checkpoint inhibitor or chemotherapy plus immunotherapy (CIT).
Read More